Literature DB >> 14695763

Construction and identification of recombinant vectors carrying herpes simplex virus thymidine kinase and cytokine genes expressed in gastric carcinoma cell line SGC7901.

Jian-Hua Zhang1, Ming-Xi Wan, Jia-Ying Yuan, Bo-Rong Pan.   

Abstract

AIM: To construct and identify the recombinant vectors carrying herpes simplex virus thymidine kinase (HSV-TK) and tumor necrosis factor alpha (TNF-alpha) or interleukin-2 (IL-2) genes expressed in gastric carcinoma cell line SGC7901.
METHODS: The fragments of HSV-TK, internal ribosome entry sites (IRES) and TNF-alpha or IL-2 genes were inserted in a TK-IRES-TNF-alpha or TK-IRES-IL-2 order into pEGFP-N(3) and pLXSN to generate the therapeutic vectors pEGFP-TT, pEGFP-TI, pL(TT)SN and pL(TI)SN respectively, which were structurally confirmed by the digestion analysis of restriction endonuclease. The former two plasmids were used for the transient expression of recombinant proteins in the target cells while pL(TT)SN and pL(TI)SN were transfected into SGC7901 cells by lipofectamine for the stable expression of objective genes through G418 selection. The protein products expressed transiently and stably in SGC7901 cells by the constructed vectors were confirmed by fluorescent microscopy and Western blot respectively.
RESULTS: The inserted fragments in all constructed plasmids were structurally confirmed to be consistent with that of the published data. In the transient expression, both pEGFP-TT and pEGFP-TI were shown expressed in nearly 50% of the transfected SGC7901 cells. Similarly, the G418 selected vectors PL(TT)SN and PL(TI)SN were confirmed to be successful in the stable expression of the objective proteins in the target cells.
CONCLUSION: The constructed recombinant vectors in the present study that can express the suicide gene TK in combination with cytokines genes may serve as the potential tools to perform more effective investigations in future for the gene therapy of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695763      PMCID: PMC4717072          DOI: 10.3748/wjg.v10.i1.26

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Current gene therapy for stomach carcinoma.

Authors:  C T Xu; L T Huang; B R Pan
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Effect of preoperative regional artery chemotherapy on proliferation and apoptosis of gastric carcinoma cells.

Authors:  Hou-Quan Tao; Shou-Chun Zou
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

3.  Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor.

Authors:  Yasuo Adachi; Shyuichiro Matsubara; Takashi Muramatsu; David T Curiel; Paul N Reynolds
Journal:  J Pediatr Surg       Date:  2002-04       Impact factor: 2.545

4.  [Effects of recombinant human bone morphogenic protein-2 and hyaluronic acid on invasion of brain glioma in vivo].

Authors:  Xiang Zhang; Jingwen Wu; Xia Li; Luoan Fu; Dakuan Gao; Hongmin Bai; Xianzhen Liu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2002-01-25

5.  Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system.

Authors:  Kyoko Hayashi; Toshimitsu Hayashi; Han-Dong Sun; Yoshio Takeda
Journal:  Hum Gene Ther       Date:  2002-02-10       Impact factor: 5.695

6.  Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice.

Authors:  Patrick Warren; Wendy Song; Eric Holle; Lilia Holmes; Yangzhang Wei; Jin Li; Thomas Wagner; Xianzhong Yu
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

7.  Tumor-specific transcriptional targeting of suicide gene therapy.

Authors:  J Qiao; M Doubrovin; B V Sauter; Y Huang; Z S Guo; J Balatoni; T Akhurst; R G Blasberg; J G Tjuvajev; S-H Chen; S L C Woo
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

8.  Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma.

Authors:  F W Floeth; N Shand; H Bojar; H B Prisack; J Felsberg; E Neuen-Jacob; A Aulich; K J Burger; W J Bock; F Weber
Journal:  Cancer Gene Ther       Date:  2001-11       Impact factor: 5.987

9.  Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes.

Authors:  E-T Wong; S-M Ngoi; C G L Lee
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

10.  Differential display of vincristine-resistance-related genes in gastric cancer SGC7901 cell.

Authors:  Xin Wang; Mei Lan; Yong-Quan Shi; Ju Lu; Yue-Xia Zhong; Han-Ping Wu; Hui-Hong Zai; Jie Ding; Kai-Cun Wu; Bo-Rong Pan; Jian-Ping Jin; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

View more
  4 in total

Review 1.  Gene therapy for gastric cancer: is it promising?

Authors:  Andreas P Sutter; Henry Fechner
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

2.  Do there exist synergistic antitumor effects by coexpression of herpes simplex virus thymidine kinase with cytokine genes on human gastric cancer cell line SGC7901?

Authors:  Jian-Hua Zhang; Ming-Xi Wan; Jia-Ying Yuan; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  The roles of macrophages and nitric oxide in interleukin-3-enhanced HSV-Sr39tk-mediated prodrug therapy.

Authors:  Ching-Fang Yu; Ji-Hong Hong; Chi-Shiun Chiang
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

4.  A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.

Authors:  Kosuke Higashi; Shoichi Hazama; Atsuhiro Araki; Kiyoshi Yoshimura; Norio Iizuka; Shigefumi Yoshino; Takafumi Noma; Masaaki Oka
Journal:  Int J Oncol       Date:  2014-07-22       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.